SG11202003096UA - Methods of treating immunotherapy-related toxicity using a gm-csf antagonist - Google Patents

Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Info

Publication number
SG11202003096UA
SG11202003096UA SG11202003096UA SG11202003096UA SG11202003096UA SG 11202003096U A SG11202003096U A SG 11202003096UA SG 11202003096U A SG11202003096U A SG 11202003096UA SG 11202003096U A SG11202003096U A SG 11202003096UA SG 11202003096U A SG11202003096U A SG 11202003096UA
Authority
SG
Singapore
Prior art keywords
methods
related toxicity
csf antagonist
immunotherapy
treating
Prior art date
Application number
SG11202003096UA
Inventor
Cameron Durrant
Dale Chappell
Original Assignee
Humanigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humanigen Inc filed Critical Humanigen Inc
Publication of SG11202003096UA publication Critical patent/SG11202003096UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202003096UA 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist SG11202003096UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762567187P 2017-10-02 2017-10-02
US201862729043P 2018-09-10 2018-09-10
PCT/US2018/053933 WO2019070680A2 (en) 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Publications (1)

Publication Number Publication Date
SG11202003096UA true SG11202003096UA (en) 2020-05-28

Family

ID=65994983

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003096UA SG11202003096UA (en) 2017-10-02 2018-10-02 Methods of treating immunotherapy-related toxicity using a gm-csf antagonist

Country Status (8)

Country Link
US (3) US10870703B2 (en)
EP (1) EP3691663A4 (en)
JP (1) JP7320498B2 (en)
CN (1) CN111757744A (en)
AU (1) AU2018345751A1 (en)
CA (1) CA3078349A1 (en)
SG (1) SG11202003096UA (en)
WO (1) WO2019070680A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
SG11202003096UA (en) 2017-10-02 2020-05-28 Humanigen Inc Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
WO2019178259A2 (en) * 2018-03-14 2019-09-19 Celledit Llc Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
US20200054675A1 (en) * 2018-06-01 2020-02-20 Washington University Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy
JP2022517461A (en) * 2018-09-10 2022-03-09 ヒューマニゲン インコーポレイティッド Treatment of immunotherapy-related toxicity using GM-CSF antagonists
CN114206346A (en) * 2019-05-03 2022-03-18 凯德药业股份有限公司 Methods of administering chimeric antigen receptor immunotherapy
JP2022535062A (en) 2019-06-03 2022-08-04 キニクサ ファーマシューティカルズ， リミテッド Cancer treatment with GM-CSF antagonists
EP4118115A4 (en) * 2020-03-08 2024-04-17 Humanigen Inc Methods for treating coronavirus infection and resulting inflammation-induced lung injury
WO2021188409A1 (en) 2020-03-15 2021-09-23 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) * 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
WO2022177815A1 (en) * 2021-02-19 2022-08-25 Edifice Health, Inc. MUCOSAL DELIVERY OF COMPOUNDS FOR MODIFYING iAGE
CU20210021A7 (en) 2021-03-30 2022-11-07 Ct Inmunologia Molecular VACCINE COMPOSITIONS DEPLETING HEMATOPOIETIC GROWTH FACTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
CN113945723B (en) * 2021-10-28 2024-03-12 复旦大学附属中山医院 System for predicting risk of occurrence of immune checkpoint inhibitor treatment-related pneumonia, storage medium and application thereof
WO2023138499A1 (en) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 Antibody preparation for specifically recognizing granulocyte-macrophage colony-stimulating factor receptor and use thereof
US20230233858A1 (en) * 2022-01-25 2023-07-27 Neuraworx Medical Technologies, Inc. Method and device to enhance waste clearance in the brain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500905A (en) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Humanized GM-CSF antibody
PT3540062T (en) 2004-11-16 2021-07-06 Humanigen Inc Immunoglobulin variable region cassette exchange
UA94403C2 (en) 2005-04-18 2011-05-10 Микромет Аг Human monoclonal antibody neutralizing granulocyte macrophage colony stimulating factor
EP3150221A1 (en) 2005-05-18 2017-04-05 MorphoSys AG Anti-gm-csf antibodies and uses therefor
HUE032584T2 (en) 2006-02-08 2017-09-28 Morphotek Inc Antigenic gm-csf peptides and antibodies to gm-csf
US20100055116A1 (en) 2006-04-13 2010-03-04 Liou Hsiou-Chi Methods and Compositions for Targeting c-Rel
EA200900709A1 (en) 2006-11-21 2009-12-30 Калобиос Фармасьютикалс, Инк. METHODS OF TREATMENT OF CHRONIC INFLAMMATORY DISEASES USING AN ANTAGONIST GM-CSF
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
WO2009126659A1 (en) 2008-04-07 2009-10-15 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
KR101852915B1 (en) 2008-04-28 2018-04-27 휴머니건, 아이엔씨. Antibodies to granulocyte-macrophage colony-stimulating factor
US20140127814A1 (en) 2010-08-10 2014-05-08 Srinivasan Chandrasegaran Generation and use of pluripotent stem cells
KR20140061379A (en) 2011-07-06 2014-05-21 모르포시스 아게 Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
FI4019041T3 (en) 2012-07-13 2023-04-03 Univ Pennsylvania Toxicity management for anti-tumor activity of cars
WO2014172470A2 (en) 2013-04-16 2014-10-23 Whitehead Institute For Biomedical Research Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
IL280215B (en) 2014-04-07 2022-07-01 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
KR20170068598A (en) 2014-10-20 2017-06-19 주노 쎄러퓨티크스 인코퍼레이티드 Methods and compositions for dosing in adoptive cell therapy
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
WO2017011670A1 (en) * 2015-07-16 2017-01-19 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions and methods for treating peritoneal cancers
CN116334205A (en) 2015-09-03 2023-06-27 诺华股份有限公司 Biomarkers for predicting cytokine release syndrome
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US20190292246A1 (en) 2016-11-03 2019-09-26 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia imhibitor
EP3580236A4 (en) 2017-02-07 2020-12-09 ME Therapeutics Inc. Anti-g-csf antibodies and uses thereof
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
SG11202003096UA (en) 2017-10-02 2020-05-28 Humanigen Inc Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
CA3101991A1 (en) 2018-06-01 2019-12-05 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer

Also Published As

Publication number Publication date
JP7320498B2 (en) 2023-08-03
US20210130488A1 (en) 2021-05-06
AU2018345751A1 (en) 2020-05-07
WO2019070680A2 (en) 2019-04-11
US20200354443A1 (en) 2020-11-12
JP2020536118A (en) 2020-12-10
EP3691663A4 (en) 2021-08-18
US20190194343A1 (en) 2019-06-27
US11673962B2 (en) 2023-06-13
WO2019070680A3 (en) 2019-05-23
CA3078349A1 (en) 2019-04-11
CN111757744A (en) 2020-10-09
EP3691663A2 (en) 2020-08-12
US10870703B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
SG11202003096UA (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
IL269196A (en) Novel inhibitors
IL281243A (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
HUE057926T2 (en) Method for the preparation of thiocarbonates
IL257061A (en) Inhibitors of ezh2
ZA201907136B (en) Ip6k inhibitors
PT3458448T (en) Methods of using fasn inhibitors
ZA201904460B (en) Inhibitors of nhe-mediated antiport
HUE058292T2 (en) Aminoimidazopyridazines as kinase inhibitors
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL272092A (en) Methods of treating behavior alterations
EP3894768C0 (en) Methods of cryo-curing
IL293192A (en) Methods of preparing indolinobenzodiazepine derivatives
IL274550A (en) Dopamine-b-hydroxylase inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
HUE054912T2 (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
SG11202101817UA (en) Methods of inhibition
GB201810835D0 (en) Methods of use
GB201801181D0 (en) Method of use
PL3629754T3 (en) Method of preparing adrosera
IL260405A (en) None-abusive derivatives of ritalin
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
RS65463B1 (en) Tandem-cumulative shot